NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we show that dysfunction of these cells accompanies human breast tumor progression. We characterized human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from the peripheral blood of healthy donors and normal breast tissue were used as controls. With disease progression, we found that expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM-1, and CD16) decreased while expression of inhibitory receptors (such as NKG2A) increased and that this correlated with decreased NK cell function, most notably cytotoxicity. Importantly, Ti-NK cells had more pronounced impairment of their cytotoxic potential than p-NK cells. We also identified several stroma-derived factors, including TGF-β1, involved in tumor-induced reduction of normal NK cell function. Our data therefore show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity. This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity.
Emilie Mamessier, Aude Sylvain, Marie-Laure Thibult, Gilles Houvenaeghel, Jocelyne Jacquemier, Rémy Castellano, Anthony Gonçalves, Pascale André, François Romagné, Gilles Thibault, Patrice Viens, Daniel Birnbaum, François Bertucci, Alessandro Moretta, Daniel Olive
Title and authors | Publication | Year |
---|---|---|
AXL: shapers of tumor progression and immunosuppressive microenvironments
Liu Y, Xu L, Dou Y, He Y |
Molecular Cancer | 2025 |
Early-Stage Luminal B-like Breast Cancer Exhibits a More Immunosuppressive Tumor Microenvironment than Luminal A-like Breast Cancer
Moura T, Caramelo O, Silva I, Silva S, Gonçalo M, Portilha MA, Moreira JN, Gil AM, Laranjeira P, Paiva A |
Biomolecules | 2025 |
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
Ehlers FA, Blise KE, Betts CB, Sivagnanam S, Kooreman LF, Hwang ES, Bos GM, Wieten L, Coussens LM |
Breast Cancer Research : BCR | 2025 |
Efficacy Evaluation of “Enhanced” Natural Killers with CISH and B2M Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients
Yuzhakova DV, Sachkova DA, Shirmanova MV, Shcheslavskiy VI, Mozherov AM, Dashinimaev EB, Baklaushev VP, Yusubalieva GM |
Modern Technologies in Medicine | 2025 |
A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum
Frey HC, Sun X, Oudeif F, Corona DL, He Z, Won T, Schultz TL, Carruthers VB, Laouar A, Laouar Y |
iScience | 2025 |
Unravelling the Connection Between Energy Metabolism and Immune Senescence/Exhaustion in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Van Campenhout J, Buntinx Y, Xiong HY, Wyns A, Polli A, Nijs J, Aerts JL, Laeremans T, Hendrix J |
Biomolecules | 2025 |
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej E, Domaradzka A, Radzka J, Drulis-Fajdasz D, Kulbacka J, Gizak A |
Cells | 2025 |
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells
Moura T, Laranjeira P, Caramelo O, Gil AM, Paiva A |
Current Oncology | 2025 |
Uncovering the heterogeneity of NK cells on the prognosis of HCC by integrating bulk and single-cell RNA-seq data
Li J, Liu Z, Zhang G, Yin X, Yuan X, Xie W, Ding X |
Frontiers in Oncology | 2025 |
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu J, Fu L, Wu R, Che L, Liu G, Ran Q, Xia Z, Liang X, Zhao G |
Frontiers in Immunology | 2025 |
Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies
Li F, Gao C, Huang Y, Qiao Y, Xu H, Liu S, Wu H |
International Journal of Biological Sciences | 2025 |
The diversity of natural killer cell functional and phenotypic states in cancer.
Rishabh K, Matosevic S |
Cancer metastasis reviews | 2025 |
KLRG1 expression induces functional exhaustion of NK cells in colorectal cancer patients
Xu C, Cao K, Ma A, Zheng M, Xu Y, Tang L |
Cancer Immunology, Immunotherapy : CII | 2025 |
A novel NKG2A alpaca nanobody targeting immune checkpoint blockade for the treatment of malignant melanoma
Guo X, Guo C, Li D, Bai Y, Abbas M, Fan R, Zhao Y |
Frontiers in Veterinary Science | 2025 |
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells
Marangio C, Milito ND, Putro E, Carnevale A, Capuano C, Zingoni A, Cippitelli M, Santoni A, Paolini R, Molfetta R |
Frontiers in Immunology | 2025 |
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A |
Journal of experimental & clinical cancer research : CR | 2024 |
Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer
Zhang H, Li Y, Liu G, Chen X |
Journal of Cancer Research and Clinical Oncology | 2024 |
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA |
Journal for ImmunoTherapy of Cancer | 2024 |
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics
Akinsipe T, Mohamedelhassan R, Akinpelu A, Pondugula SR, Mistriotis P, Avila LA, Suryawanshi A |
Frontiers in immunology | 2024 |
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
Szulc A, Woźniak M |
Cancers | 2024 |
Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression
Kim N, Yi E, Lee E, Park HJ, Kim HS |
Frontiers in immunology | 2024 |
No time to die: Epigenetic regulation of natural killer cell survival.
Hermans L, O'Sullivan TE |
Immunological Reviews | 2024 |
Predictive value of lymphocyte subsets and lymphocyte-to-monocyte ratio in assessing the efficacy of neoadjuvant therapy in breast cancer
Zhang H, Li Y, Liu YW, Liu YG, Chen X |
Scientific Reports | 2024 |
BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors
Felgueres MJ, Esteso G, García-Jiménez ÁF, Dopazo A, Aguiló N, Mestre-Durán C, Martínez-Piñeiro L, Pérez-Martínez A, Reyburn HT, Valés-Gómez M |
Scientific Reports | 2024 |
Natural killer cells in cancer immunotherapy
Wang D, Dou L, Sui L, Xue Y, Xu S |
MedComm | 2024 |
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients
Dalle S, Verronese E, N\u2019Kodia A, Bardin C, Rodriguez C, Andrieu T, Eberhardt A, Chemin G, Hasan U, Le-Bouar M, Caramel J, Amini-Adle M, Bendriss-Vermare N, Dubois B, Caux C, Ménétrier-Caux C |
OncoImmunology | 2024 |
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance
Huang YH, Yoon CH, Gandhi A, Hanley T, Castrillon C, Kondo Y, Lin X, Kim W, Yang C, Driouchi A, Carroll M, Gray-Owen SD, Wesemann DR, Drake CG, Bertagnolli MM, Beauchemin N, Blumberg RS |
2024 | |
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets
Hofman T, Ng SW, Garcés-Lázaro I, Heigwer F, Boutros M, Cerwenka A |
Journal for ImmunoTherapy of Cancer | 2024 |
Human NK cells and cancer
Cantoni C, Falco M, Vitale M, Pietra G, Munari E, Pende D, Mingari MC, Sivori S, Moretta L |
OncoImmunology | 2024 |
Accumulation of CD56+ CD16- Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer
Kim R, Kawai A, Wakisaka M, Shimoyama M, Yasuda N, Ito M, Kin T, Arihiro K |
World Journal of Oncology | 2024 |
Natural Killer-Based Therapy: A Prospective Thought for Cancer Treatment Related to Diversified Drug Delivery Pathways
Zang J, Mei Y, Zhu S, Yin S, Feng N, Ci T, Lyu Y |
Pharmaceutics | 2024 |
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei
Zhao Q, Wei T, Ma R, Fu Y, Yang R, Su Y, Yu Y, Li B, Li Y |
Cancer biology & medicine | 2024 |
HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression
Choi WS, Kwon H, Yi E, Lee H, Kim JM, Park HJ, Choi EJ, Choi ME, Sung YH, Won CH, Sung CO, Kim HS |
Advanced Science | 2024 |
Natural Killer cells at the frontline in the fight against cancer
Coënon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M |
Cell Death & Disease | 2024 |
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S |
Cellular and Molecular Immunology | 2024 |
Intracellular checkpoints for NK cell cancer immunotherapy.
Huang Y, Tian Z, Bi J |
Frontiers of medicine | 2024 |
STYK1 mediates NK cell anti-tumor response through regulating CCR2 and trafficking
He J, He Y, Biao R, Wei Y, Dong Z, Du J |
Journal of Translational Medicine | 2024 |
Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.
Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor PPC, Buschow S, Sprengers D, Zhou G |
Journal for immunotherapy of cancer | 2024 |
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization
Chen S, Zhu H, Jounaidi Y |
Signal Transduction and Targeted Therapy | 2024 |
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y, Wang Q, Li Y, Hu F, Ren H |
Molecular cancer | 2024 |
CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers
Raninga PV, Zeng B, Moi D, Trethowan E, Saletta F, Venkat P, Mayoh C, D\u2019Souza RC, Day BW, Shai-Hee T, Vittorio O, Mazzieri R, Dolcetti R, Khanna KK |
Oncogene | 2024 |
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.
Viel S, Vivier E, Walzer T, Marçais A |
Nature reviews. Drug discovery | 2024 |
Alteration of the NKG2A on NK cells and ligands on exosomes in the peripheral blood after prostatectomy are key regulators of natural killer cell activity
Yu-Chuan Lu, Chen-Hsun Ho, Jian-Hua Hong, Ming-Chieh Kuo, Fu-Shan Jaw, Jason Chia-Hsien Cheng, Chao-Yuan Huang, Koping Chang, Jung-An Lin, Hsiu-Ni Kung |
Molecular Oncology | 2023 |
The inhibitory NKR-P1B receptor regulates NK cell-mediated mammary tumor immunosurveillance in mice
Al Olabi R, Hendy AE, Alkassab MB, Alnajm K, Elias M, Ibrahim M, Carlyle JR, Makrigiannis AP, Rahim MM |
OncoImmunology | 2023 |
Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients
Rodríguez IJ, Bernal-Estévez DA, Llano-León M, Bonilla CE, Parra-López CA |
PloS one | 2023 |
Status and prognostic value of immunological biomarkers of breast cancer
Murazawa C, Hashimoto N, Kuraishi K, Motoyama M, Hashimoto SI, Ikeuchi M, Norimura S, Matsunaga T, Teramoto K, Haba R, Abe N, Yajima T, Kontani K |
Oncology Letters | 2023 |
Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics
Coyle KM, Hawke LG, Ormiston ML |
Cancers | 2023 |
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano MF, Bruni S, Mauro FL, Schillaci R |
Cancers | 2023 |
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yu Y |
Cancers | 2023 |
Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Chan MK, Chan EL, Ji ZZ, Chan AS, Li C, Leung KT, To KF, Tang PM |
2023 | |
Harnessing the power of memory-like NK cells to fight cancer
Foo YY, Tiah A, Aung SW |
Clinical & Experimental Immunology | 2023 |
TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma
Cheng S, Li J, Xu M, Bao Q, Wu J, Sun P, Han B |
Analytical cellular pathology (Amsterdam) | 2023 |
The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
Kaulfuss M, Mietz J, Fabri A, vom Berg J, Münz C, Chijioke O |
Scientific Reports | 2023 |
Comprehensive analysis of angiogenesis pattern and related immune landscape for individual treatment in osteosarcoma.
Liao Z, Li M, Wen G, Wang K, Yao D, Chen E, Liang Y, Xing T, Su K, Liang C, Che Z, Ning Q, Tang J, Yan W, Li Y, Huang L |
npj Precision Oncology | 2023 |
Immune evasion and therapeutic opportunities based on natural killer cells
Zhang J, Guo F, Li L, Zhang S, Wang Y |
Chinese Journal of Cancer Research | 2023 |
Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer
Liu Z, Ding M, Qiu P, Pan K, Guo Q |
Frontiers in immunology | 2023 |
Circulating natural killer cells and their association with breast cancer and its clinico-pathological characteristics
Marcelin HN, Dasse RS, Yeboah RO, Tariam AD, Kagambega AG, Oseni AM, Kouassi YK, Bilé MA, Toure M, Thakar M, Adoubi I, Kizub D |
ecancermedicalscience | 2023 |
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, Noh JY |
Frontiers in immunology | 2023 |
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M, Lam KP, Xu S |
Frontiers in immunology | 2023 |
Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework
Feng Q, Huang Z, Song L, Wang L, Lu H, Wu L |
European Journal of Medical Research | 2023 |
Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment
Paolini R, Molfetta R |
Cancers | 2023 |
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
Zeller T, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, Kellner C |
Frontiers in immunology | 2023 |
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van \u2018t Veer LJ, Horlings HM |
Breast Cancer Research | 2023 |
Highly expressed RPLP2 inhibits ferroptosis to promote hepatocellular carcinoma progression and predicts poor prognosis
Guo J, Huang M, Deng S, Wang H, Wang Z, Yan B |
Cancer Cell International | 2023 |
Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation
Mälarstig A, Grassmann F, Dahl L, Dimitriou M, McLeod D, Gabrielson M, Smith-Byrne K, Thomas CE, Huang TH, Forsberg SK, Eriksson P, Ulfstedt M, Johansson M, Sokolov AV, Schiöth HB, Hall P, Schwenk JM, Czene K, Hedman ÅK |
Nature Communications | 2023 |
Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response
Hashemi M, Daneii P, Zandieh MA, Raesi R, Zahmatkesh N, Bayat M, Abuelrub A, Khazaei Koohpar Z, Aref AR, Zarrabi A, Rashidi M, Salimimoghadam S, Entezari M, Taheriazam A, Khorrami R |
Non-coding RNA Research | 2023 |
The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy
Wei L, Xiang Z, Zou Y |
International journal of molecular sciences | 2023 |
Strategies to overcome low MHC-I expression in paediatric and adult tumours
Guillaume J, Perzolli A, Boes M |
2023 | |
Fat Biology in Triple-Negative Breast Cancer: Immune Regulation, Fibrosis, and Senescence
Lee CM, Fang S |
Journal of Obesity & Metabolic Syndrome | 2023 |
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
Jacob A Myers, Dawn Schirm, Laura Bendzick, Rachel Hopps, Carly Selleck, Peter Hinderlie, Martin Felices, Jeffrey Miller |
JCI Insight | 2022 |
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
H Lin, Y Liu, D Lofland, J Lin |
Cancers | 2022 |
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
W Fridman, M Meylan, F Petitprez, C Sun, A Italiano, C Sautès-Fridman |
Nature Reviews Clinical Oncology | 2022 |
Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies
C Vitale, M Marzagalli, S Scaglione, A Dondero, C Bottino, R Castriconi |
Cancers | 2022 |
Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function
J Li, T OSullivan |
Frontiers in immunology | 2022 |
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes
L Rethacker, M Boy, V Bisio, F Roussin, J Denizeau, A Vincent-Salomon, E Borcoman, C Sedlik, E Piaggio, A Toubert, N Dulphy, A Caignard |
OncoImmunology | 2022 |
Innate Immunity and Cancer Pathophysiology
L Maiorino, J Daßler-Plenker, L Sun, M Egeblad |
Annual review of pathology | 2022 |
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
N Maskalenko, D Zhigarev, K Campbell |
Nature Reviews Drug Discovery | 2022 |
Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer
Medjouel Khlifi H, Guia S, Vivier E, Narni-Mancinelli E |
Frontiers in immunology | 2022 |
Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.
Kansler ER, Dadi S, Krishna C, Nixon BG, Stamatiades EG, Liu M, Kuo F, Zhang J, Zhang X, Capistrano K, Blum KA, Weiss K, Kedl RM, Cui G, Ikuta K, Chan TA, Leslie CS, Hakimi AA, Li MO |
Nature Immunology | 2022 |
NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma
Zheng G, Han T, Hu X, Yang Z, Wang J, Wen Z, Li H, Wang H |
Frontiers in Oncology | 2022 |
Plasticity of NK cells in Cancer
Corvino D, Kumar A, Bald T |
Frontiers in immunology | 2022 |
Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment
Busà R, Bulati M, Badami E, Zito G, Maresca DC, Conaldi PG, Ercolano G, Ianaro A |
Frontiers in Cell and Developmental Biology | 2022 |
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
Peipp M, Klausz K, Boje AS, Zeller T, Zielonka S, Kellner C |
Clinical & Experimental Immunology | 2022 |
The Significance of MicroRNAs in the Molecular Pathology of Brain Metastases
Siegl F, Vecera M, Roskova I, Smrcka M, Jancalek R, Kazda T, Slaby O, Sana J |
Cancers | 2022 |
Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances
Nikoo M, Rudiansyah M, Bokov DO, Jainakbaev NT, Suksatan W, Ansari MJ, Thangavelu L, Chupradit S, Zamani A, Adili A, Shomali N, Akbari M |
Journal of Cellular and Molecular Medicine | 2022 |
NK cell dysfunction is linked with disease severity in SARS‐CoV‐2 patients
Dizaji Asl K, Mazloumi Z, Majidi G, Kalarestaghi H, Sabetkam S, Rafat A |
Cell Biochemistry and Function | 2022 |
Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Bozorgi A, Bozorgi M, Khazaei M |
Cellular oncology (Dordrecht) | 2022 |
Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer
Feng J, Yi J, Zouxu X, Li J, Xiong Z, Huang X, Zhong W, Huang W, Ye F, Wang X |
Cancer Medicine | 2022 |
Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews
González-Moles MÁ, Warnakulasuriya S, López-Ansio M, Ramos-García P |
Cancers | 2022 |
The role of the natural killer (NK) cell modulation in breast cancer incidence and progress.
Razeghian E, Kameh MC, Shafiee S, Khalafi F, Jafari F, Asghari M, Kazemi K, Ilkhani S, Shariatzadeh S, Haj-Mirzaian A |
Molecular Biology Reports | 2022 |
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
Seliger B, Koehl U |
Frontiers in immunology | 2022 |
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.
Azoulay T, Slouzky I, Karmona M, Filatov M, Hayun M, Ofran Y, Sarig G, Ringelstein-Harlev S |
Cancer Immunology, Immunotherapy | 2022 |
NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.
Battin C, Kaufmann G, Leitner J, Tobias J, Wiedermann U, Rölle A, Meyer M, Momburg F, Steinberger P |
Immunology | 2022 |
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T |
Journal for ImmunoTherapy of Cancer | 2022 |
N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor
Lou C, Wu K, Shi J, Dai Z, Xu Q |
Journal for ImmunoTherapy of Cancer | 2022 |
TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
Kaminski MF, Bendzick L, Hopps R, Kauffman M, Kodal B, Soignier Y, Hinderlie P, Walker JT, Lenvik TR, Geller MA, Miller JS, Felices M |
Journal for ImmunoTherapy of Cancer | 2022 |
TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy
Zhu X, Yuan Z, Cheng S, Wang H, Liao Y, Zhou D, Wu Z |
World journal of surgical oncology | 2022 |
The Next Generation of Cellular Immunotherapy: CAR-NK Cells
Moscarelli J, Zahavi D, Maynard R, Weiner L |
2022 | |
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L |
Frontiers in Genetics | 2022 |
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza-Valderrey A, Alvarez M, De Maria A, Margolin K, Melero I, Ascierto ML |
Cells | 2022 |
SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.
Jafarzadeh A, Gosain R, Mortazavi SMJ, Nemati M, Jafarzadeh S, Ghaderi A |
International journal of hematology-oncology and stem cell research | 2022 |
DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response.
Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden DL, Chan CL, Al-Eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S |
Nature Communications | 2022 |
Protective Effect of the Polysaccharides from Taraxacum mongolicum Leaf by Modulating the p53 Signaling Pathway in H22 Tumor-Bearing Mice
Chen P, Chen Y, Yan ZQ, Ding SY, Liu HP, Tu JQ, Zhang XW |
Foods | 2022 |
Suppression of CD56(bright) NK cells in breast cancer patients is associated with the PD-1 and TGF-βRII expression.
Arianfar E, Khandoozi SR, Mohammadi S, Memarian A |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2022 |
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
Xiao J, Zhang T, Gao F, Zhou Z, Shu G, Zou Y, Yin G |
Cancers | 2022 |
Harnessing NK Cells to Control Metastasis.
Deng X, Terunuma H |
Human vaccines | 2022 |
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
Zhang Q, Ye M, Lin C, Hu M, Wang Y, Lou Y, Kong Q, Zhang J, Li J, Zhang Y, Yang T, Sun X, Yao W, Hua Y, Huang H, Xu M, Wang X, Yu X, Tao W, Liu R, Gao Y, Wang T, Wang J, Wei X, Wu J, Yu Z, Zhang C, Yu C, Bai X, Liang T |
Gut | 2022 |
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
K Slattery, E Woods, V Zaiatz-Bittencourt, S Marks, S Chew, M Conroy, C Goggin, C MacEochagain, J Kennedy, S Lucas, DK Finlay, CM Gardiner |
Journal for ImmunoTherapy of Cancer | 2021 |
NK and NKT cells have distinct properties and functions in cancer
X Liu, L Li, F Si, L Huang, Y Zhao, C Zhang, DF Hoft, G Peng |
Oncogene | 2021 |
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
KA Shaver, TJ Croom-Perez, AJ Copik |
Frontiers in immunology | 2021 |
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
E Shklovskaya, H Rizos |
International journal of molecular sciences | 2021 |
Overcoming TGFβ-mediated immune evasion in cancer
DV Tauriello, E Sancho, E Batlle |
Nature Reviews Cancer | 2021 |
The Role of NK Cells in EBV Infection and EBV-Associated NPC
YT Png, AZ Yang, MY Lee, MJ Chua, CM Lim |
Viruses | 2021 |
Lipid Metabolism in Tumor Immunity
Y Li |
2021 | |
The Interplay of Exosomes and NK Cells in Cancer Biology
IA Batista, ST Quintas, SA Melo |
Cancers | 2021 |
Targeting the purinergic pathway in breast cancer and its therapeutic applications
JB de Araújo, VV Kerkhoff, SF de Oliveira Maciel, DT de Resende e Silva |
Purinergic Signalling | 2021 |
Arrested development: suppression of NK cell function in the tumor microenvironment
L Riggan, S Shah, TE OSullivan |
IBMS BoneKEy | 2021 |
Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone
T Pilli, S Cardinale, S Cantara, G Dalmazio, R Forleo, M Capezzone, C Bassi, M Negrini, M Ferracin, MG Castagna |
Endocrine | 2021 |
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
M Deng, H Chen, X Liu, R Huang, Y He, B Yoo, J Xie, S John, N Zhang, Z An, CC Zhang |
2021 | |
The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery
S Batalha, S Ferreira, C Brito |
Cancers | 2021 |
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
I Lodewijk, SP Nunes, R Henrique, C Jerónimo, M Dueñas, JM Paramio |
Clinical Epigenetics | 2021 |
Systemic immunity in cancer
KJ Hiam-Galvez, BM Allen, MH Spitzer |
Nature Reviews Cancer | 2021 |
Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia
VA Cianga, LC Catafal, P Cianga, MP Tanasa, M Cherry, P Collet, E Tavernier, D Guyotat, C Rusu, CM Aanei |
Frontiers in immunology | 2021 |
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
C Zalfa, S Paust |
Frontiers in immunology | 2021 |
High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia
K Li, L Chen, H Zhang, L Wang, K Sha, X Du, D Li, Z Zheng, R Pei, Y Lu, H Tong |
Aging | 2021 |
Immune System Effects on Breast Cancer
JN Amens, G Bahçecioglu, P Zorlutuna |
Cellular and Molecular Bioengineering | 2021 |
Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases
DM Radomska-Leśniewska, A Białoszewska, P Kamiński |
Cells | 2021 |
Immune Circuits to Shape Natural Killer Cells in Cancer
I Mattiola |
Cancers | 2021 |
Transcription factor Zhx2 restricts NK cell maturation and suppresses their antitumor immunity
S Tan, X Guo, M Li, T Wang, Z Wang, C Li, Z Wu, N Li, L Gao, X Liang, C Ma |
Journal of Experimental Medicine | 2021 |
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis
R Takei, T Miyashita, S Takada, H Tajima, I Ninomiya, H Takamura, S Fushida, A Harashima, S Munesue, S Yagi, N Inaki, T Ohta, Y Yamamoto |
Cancer Immunology, Immunotherapy | 2021 |
The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses
S Roma, L Carpen, A Raveane, F Bertolini |
Cancers | 2021 |
Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice
M Ghasemzadeh, A Ghasemzadeh, E Hosseini |
Human Immunology | 2021 |
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30 + Malignancies
LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, M Becker-Hapak, R Basar, M Foster, LG Melo, CC Neal, E McClain, M Daher, AK Cortes, S Desai, FW Lim, MC Mendt, T Schappe, L Li, H Shaim, M Shanley, EL Ensley, N Uprety, P Wong, E Liu, SO Ang, R Cai, V Nandivada, V Mohanty, Q Miao, Y Shen, N Baran, NW Fowlkes, K Chen, L Muniz-Feliciano, RE Champlin, YL Nieto, J Koch, M Treder, W Fischer, OK Okamoto, EJ Shpall, TA Fehniger, K Rezvani |
Clinical cancer research | 2021 |
NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton
EH Lee, DC Wong, JL Ding |
Frontiers in immunology | 2021 |
TIGIT + TIM-3 + NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
L Yu, X Liu, X Wang, F Yan, P Wang, Y Jiang, J Du, Z Yang |
OncoImmunology | 2021 |
CAR‐NK cell in cancer immunotherapy; A promising frontier
F Marofi, OF AbdulRasheed, HS Rahman, HS Budi, AT Jalil, AV Yumashev, A Hassanzadeh, M Yazdanifar, R Motavalli, MS Chartrand, M Ahmadi, A CidArreguid, M Jarahian |
Cancer Science | 2021 |
Epigenetic quantification of circulating immune cells in peripheral blood of triple-negative breast cancer patients
M Manoochehri, T Hielscher, N Borhani, C Gerhäuser, O Fletcher, AJ Swerdlow, YD Ko, H Brauch, T Brüning, U Hamann |
Clinical Epigenetics | 2021 |
Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation
L Milling, D Garafola, Y Agarwal, S Wu, A Thomas, N Donahue, J Adams, N Thai, H Suh, D Irvine |
Cancer immunology research | 2021 |
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis
MT Palano, M Gallazzi, M Cucchiara, AD Barbaro, D Gallo, B Bassani, A Bruno, L Mortara |
Human vaccines | 2021 |
C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models
Nandagopal S, Li CG, Xu Y, Sodji QH, Graves EE, Giaccia AJ |
Cancer immunology research | 2021 |
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
JM Chauvin, M Ka, O Pagliano, C Menna, Q Ding, R DeBlasio, C Sanders, J Hou, XY Li, S Ferrone, D Davar, JM Kirkwood, RJ Johnston, AJ Korman, MJ Smyth, HM Zarour |
Clinical cancer research | 2020 |
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
SK Chauhan, U Koehl, S Kloess |
Cancers | 2020 |
Targeting novel inhibitory receptors in cancer immunotherapy
QQ Ding, JM Chauvin, HM Zarour |
Seminars in Immunology | 2020 |
Inflammasome Deletion Promotes Anti-tumor NK Cell Function in an IL-1/IL-18 Independent Way in Murine Invasive Breast Cancer
B Guey, M Bodnar-Wachtel, A Drouillard, A Eberhardt, M Pratviel, N Goutagny, N Bendriss-Vermare, I Puisieux, C Caux, T Walzer, V Petrilli |
Frontiers in Oncology | 2020 |
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
A Ben-Shmuel, G Biber, M Barda-Saad |
Frontiers in immunology | 2020 |
NK cells for cancer immunotherapy
N Shimasaki, A Jain, D Campana |
Nature Reviews Drug Discovery | 2020 |
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
S Mantesso, D Geerts, J Spanholtz, L Kučerová |
Frontiers in immunology | 2020 |
Mechanisms of Resistance to NK Cell Immunotherapy
C Sordo-Bahamonde, M Vitale, S Lorenzo-Herrero, A López-Soto, S Gonzalez |
Cancers | 2020 |
Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
C Fionda, H Stabile, C Cerboni, A Soriani, A Gismondi, M Cippitelli, A Santoni |
Journal of Clinical Medicine | 2020 |
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
L Quatrini, FR Mariotti, E Munari, N Tumino, P Vacca, L Moretta |
Cancers | 2020 |
Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells
T Ebihara |
Cells | 2020 |
The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas
L Annaratone, E Cascardi, E Vissio, I Sarotto, E Chmielik, A Sapino, E Berrino, C Marchiò |
Pathobiology | 2020 |
The Tumor Microenvironment—A Metabolic Obstacle to NK Cells’ Activity
J Domagala, M Lachota, M Klopotowska, A Graczyk-Jarzynka, A Domagala, A Zhylko, K Soroczynska, M Winiarska |
Cancers | 2020 |
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
Z Hu |
Scientific Reports | 2020 |
Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell
C Yang, Y Li, Y Yang, Z Chen |
Journal of Immunology Research | 2020 |
Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro
MM Morgan, LA Schuler, JC Ciciliano, BP Johnson, ET Alarid, DJ Beebe |
Integrative biology : quantitative biosciences from nano to macro | 2020 |
NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
K Shimizu, T Iyoda, S Yamasaki, N Kadowaki, A Tojo, S Fujii |
Cancers | 2020 |
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
A Yaqinuddin, J Kashir |
Medical Hypotheses | 2020 |
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
MP Trefny, M Kaiser, MA Stanczak, P Herzig, S Savic, M Wiese, D Lardinois, H Läubli, F Uhlenbrock, A Zippelius |
Cancer Immunology, Immunotherapy | 2020 |
Renal cell tumors convert natural killer cells to a proangiogenic phenotype
Y Guan, CB Chambers, T Tabatabai, H Hatley, KR Delfino, K Robinson, SR Alanee, S Ran, DS Torry, A Wilber |
Oncotarget | 2020 |
IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma
Y Zheng, Y Li, B Tang, Q Zhao, D Wang, Y Liu, M Guo, S Zhao, Y Qi, Y Zhang, L Huang |
Cancer Immunology, Immunotherapy | 2020 |
miRNAs in Health and Disease: A Focus on the Breast Cancer Metastatic Cascade towards the Brain
M Sereno, M Videira, I Wilhelm, IA Krizbai, MA Brito |
Cells | 2020 |
Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
H Chen, Y Chen, M Deng, S John, X Gui, A Kansagra, W Chen, J Kim, C Lewis, G Wu, J Xie, L Zhang, R Huang, X Liu, H Arase, Y Huang, H Yu, W Luo, N Xia, N Zhang, Z An, CC Zhang |
Journal for ImmunoTherapy of Cancer | 2020 |
NK cells beat T cells at early breast cancer control
A Buque, N Bloy, G Petroni, G Kroemer, L Galluzzi |
OncoImmunology | 2020 |
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
M Sadeghalvad, HR Mohammadi-Motlagh, N Rezaei |
Breast Cancer Research and Treatment | 2020 |
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
J Russick, PE Joubert, M Gillard-Bocquet, C Torset, M Meylan, F Petitprez, MA Dragon-Durey, S Marmier, A Varthaman, N Josseaume, C Germain, J Goc, MC Dieu-Nosjean, P Validire, L Fournel, L Zitvogel, G Bindea, A Lupo, D Damotte, M Alifano, I Cremer |
Journal for ImmunoTherapy of Cancer | 2020 |
Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity
VW Xue, JY Chung, CA Córdoba, AH Cheung, W Kang, EW Lam, KT Leung, KF To, HY Lan, PM Tang |
Cancers | 2020 |
Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells
S Wieckowski, C Avenal, AV Orjalo, D Gygax, F Cymer |
Frontiers in immunology | 2020 |
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
S Pesce, S Trabanelli, CD Vito, M Greppi, V Obino, F Guolo, P Minetto, M Bozzo, M Calvi, E Zaghi, S Candiani, RM Lemoli, C Jandus, D Mavilio, E Marcenaro |
Cancers | 2020 |
Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER/PR/HER2+ patients
MH Larki, S Barani, AR Talei, A Ghaderi |
Genes and Immunity | 2020 |
Tumor-Infiltrating Natural Killer Cells
B Cózar, M Greppi, S Carpentier, E Narni-Mancinelli, L Chiossone, E Vivier |
Cancer Discovery | 2020 |
Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer
I Linares-Galiana, MA Berenguer-Frances, R Cañas-Cortés, M Pujol-Canadell, S Comas-Antón, E Martínez, M Laplana, H Pérez-Montero, MJ Pla-Farnós, A Navarro-Martin, M Nuñez, B Both, F Guedea |
Journal of Radiation Research | 2020 |
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
SV Fernandez, AW MacFarlane, M Jillab, MF Arisi, J Yearley, L Annamalai, Y Gong, KQ Cai, RK Alpaugh, M Cristofanilli, KS Campbell |
Breast Cancer Research | 2020 |
The Role of Innate Immunity in the Pathogenesis of Breast Cancer
D Grebić, T Gulić, A Starčević, M Alvirović, GB Zagorac, PV Zujić, DV Vujaklija |
Breast Care | 2020 |
Oral cancer cell‑derived exosomes modulate natural killer cell activity by regulating the receptors on these cells
X Zhu, X Qin, X Wang, Y Wang, W Cao, J Zhang, W Chen, X Zhu, X Qin, X Wang, Y Wang, W Cao, J Zhang, W Chen, X Zhu, X Qin, X Wang, Y Wang, W Cao, J Zhang, W Chen |
International journal of molecular medicine | 2020 |
Natural Killer Cells Expanded and Preactivated Exhibit Enhanced Antitumor Activity against Different Tumor Cells in Vitro
BK Biswas, SA Guru, MP Sumi, E Jamatia, RK Gupta, P Lali, BC Konar, A Saxena, R Mir |
Asian Pacific Journal of Cancer Prevention | 2020 |
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway
Maite Alvarez, Federico Simonetta, Jeanette Baker, Antonio Pierrini, Arielle S Wenokur, Alyssa R Morrison, William Murphy, Robert Negrin |
JCI Insight | 2019 |
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging
Denise Muñoz, Steve Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam Freund, Francis Rodier, Jennifer Wu, Pierre-Yves Desprez, David Raulet, Peter S Nelson, Laura J van 't Veer, Judith Campisi, Jean-Philippe Coppé |
JCI Insight | 2019 |
blocking expression of inhibitory receptor nkg2a overcomes tumor resistance to nk cells
TAKAHIRO KAMIYA, SEE VOON SEOW, Desmond Wong, MURRAY ROBINSON, Dario Campana |
Journal of Clinical Investigation | 2019 |
Killers 2.0: NK Cell Therapies at the Forefront of Cancer Control
Jonathan J. Hodgins, Sarwat Khan, Maria M. Park, Rebecca Auer, Michele Ardolino |
Journal of Clinical Investigation | 2019 |
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
H Stamm, L Oliveira-Ferrer, EM Grossjohann, J Muschhammer, V Thaden, F Brauneck, R Kischel, V Müller, C Bokemeyer, W Fiedler, J Wellbrock |
OncoImmunology | 2019 |
Monalizumab: inhibiting the novel immune checkpoint NKG2A
T van Hall, P André, A Horowitz, DF Ruan, L Borst, R Zerbib, E Narni-Mancinelli, SH van der Burg, E Vivier |
Journal for ImmunoTherapy of Cancer | 2019 |
Harnessing NK Cells for Cancer Treatment
P Minetto, F Guolo, S Pesce, M Greppi, V Obino, E Ferretti, S Sivori, C Genova, RM Lemoli, E Marcenaro |
Frontiers in immunology | 2019 |
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
G Nayyar, Y Chu, MS Cairo |
Frontiers in Oncology | 2019 |
Dysregulation of Natural Killer Cells in Obesity
D OShea, AE Hogan |
Cancers | 2019 |
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
A Frazao, L Rethacker, M Messaoudene, MF Avril, A Toubert, N Dulphy, A Caignard |
Frontiers in immunology | 2019 |
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
C Ménétrier-Caux, I Ray-Coquard, JY Blay, C Caux |
Journal for ImmunoTherapy of Cancer | 2019 |
A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease
O Lucar, RK Reeves, S Jost |
Frontiers in immunology | 2019 |
NK Cell Dysfunction and Checkpoint Immunotherapy
J Bi, Z Tian |
Frontiers in immunology | 2019 |
Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study
K Wang, HL Li, YF Xiong, Y Shi, ZY Li, J Li, X Zhang, HY Li |
Cancer Medicine | 2019 |
Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation
SP Hood, GA Foulds, H Imrie, S Reeder, SE McArdle, M Khan, AG Pockley |
Frontiers in immunology | 2019 |
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
MC Chang, HI Cheng, K Hsu, YN Hsu, CW Kao, YF Chang, KH Lim, CG Chen |
Frontiers in immunology | 2019 |
Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors
C Yang, M Du, F Yan, Z Chen |
Frontiers in pharmacology | 2019 |
Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function
C Degos, M Heinemann, J Barrou, N Boucherit, E Lambaudie, A Savina, L Gorvel, D Olive |
Frontiers in immunology | 2019 |
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
A Burlion, RN Ramos, P KC, K Sendeyo, A Corneau, C Ménétrier-Caux, E Piaggio, D Olive, C Caux, G Marodon |
OncoImmunology | 2019 |
Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects
B Bassani, D Baci, M Gallazzi, A Poggi, A Bruno, L Mortara |
Cancers | 2019 |
TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
Y Zheng, Y Li, J Lian, H Yang, F Li, S Zhao, Y Qi, Y Zhang, L Huang |
Journal of Translational Medicine | 2019 |
Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer
J Zhao, HA Schlößer, Z Wang, J Qin, J Li, F Popp, MC Popp, H Alakus, SH Chon, HP Hansen, WF Neiss, KW Jauch, CJ Bruns, Y Zhao |
Cancers | 2019 |
CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse
G Taouk, O Hussein, M Zekak, A Abouelghar, Y Al-Sarraj, EM Abdelalim, M Karam |
Scientific Reports | 2019 |
Human peripheral blood DNAM-1 neg NK cells are a terminally differentiated subset with limited effector functions
KA Stannard, S Lemoine, NJ Waterhouse, F Vari, L Chatenoud, MK Gandhi, L Martinet, MJ Smyth, C Guillerey |
Blood Advances | 2019 |
The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
A Naik, AM Monjazeb, J Decock |
Frontiers in immunology | 2019 |
Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment
PR Nath, D Pal-Nath, A Mandal, MC Cam, AL Schwartz, DD Roberts |
Cancer immunology research | 2019 |
Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis
S Pesce, V Belgrano, M Greppi, S Carlomagno, M Squillario, A Barla, MD Chiesa, SD Domenico, D Mavilio, L Moretta, S Candiani, S Sivori, FD Cian, E Marcenaro |
Frontiers in immunology | 2019 |
NK Cell Plasticity in Cancer
S Liu, P Dhar, JD Wu |
Journal of Clinical Medicine | 2019 |
The Immune Microenvironment of Breast Cancer Progression
Tower, Ruppert, Britt |
Cancers | 2019 |
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Shembrey, Huntington, Hollande |
Cancers | 2019 |
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
H Sun, C Sun |
Frontiers in immunology | 2019 |
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
M Desbois, C Béal, M Charrier, B Besse, G Meurice, N Cagnard, Y Jacques, D Béchard, L Cassard, N Chaput |
Journal for ImmunoTherapy of Cancer | 2019 |
Immunometabolism: A new target for improving cancer immunotherapy
Guo C, Chen S, Liu W, Ma Y, Li J, Fisher PB, Fang X, Wang XY |
Advances in cancer research | 2019 |
A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients.
Kim R, Kawai A, Wakisaka M, Funaoka Y, Yasuda N, Hidaka M, Morita Y, Ohtani S, Ito M, Arihiro K |
Cancer Immunology, Immunotherapy | 2019 |
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation
Rebecca Vartuli, Hengbo Zhou, Lingdi Zhang, Rani Powers, Jared Klarquist, Pratyaydipta Rudra, Melanie Vincent, Debashis Ghosh, James Costello, Ross M Kedl, Jill Slansky, Rui Zhao, Heide Ford |
Journal of Clinical Investigation | 2018 |
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function
A Stiff, P Trikha, B Mundy-Bosse, E McMichael, TA Mace, B Benner, K Kendra, A Campbell, S Gautam, D Abood, I Landi, V Hsu, M Duggan, R Wesolowski, M Old, JH Howard, L Yu, N Stasik, T Olencki, N Muthusamy, S Tridandapani, JC Byrd, M Caligiuri, WE Carson |
Clinical cancer research | 2018 |
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
H Stamm, J Wellbrock, W Fiedler |
Mammalian Genome | 2018 |
Targeting PVR (CD155) and its receptors in anti-tumor therapy
PK Brlić, TL Roviš, G Cinamon, P Tsukerman, O Mandelboim, S Jonjić |
Cellular and Molecular Immunology | 2018 |
Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients
A Abouelghar, R Hasnah, G Taouk, M Saad, M Karam |
Oncotarget | 2018 |
Mechanisms of immune evasion in breast cancer
JP Bates, R Derakhshandeh, L Jones, TJ Webb |
BMC Cancer | 2018 |
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
SM Lluesma, M Graciotti, C Chiang, L Kandalaft |
Human vaccines | 2018 |
Natural killer cells in liver diseases
M Zheng, H Sun, Z Tian |
Frontiers of Medicine | 2018 |
Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
GA Foulds, J Vadakekolathu, TM Abdel-Fatah, D Nagarajan, S Reeder, C Johnson, S Hood, PM Moseley, SY Chan, AG Pockley, S Rutella, SE McArdle |
Frontiers in immunology | 2018 |
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
PM Tang, PC Tang, JY Chung, JS Hung, QM Wang, GY Lian, J Sheng, XR Huang, KF To, HY Lan |
Journal of visualized experiments : JoVE | 2018 |
Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study
CC Chen, YT Chang, HN Liu, YJ Chen |
Cancer Medicine | 2018 |
IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction
NJ Easom, KA Stegmann, L Swadling, LJ Pallett, AR Burton, D Odera, N Schmidt, WC Huang, G Fusai, B Davidson, MK Maini |
Frontiers in immunology | 2018 |
Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice
RM Loftus, N Assmann, N Kedia-Mehta, KL OBrien, A Garcia, C Gillespie, JL Hukelmann, PJ Oefner, AI Lamond, CM Gardiner, K Dettmer, DA Cantrell, LV Sinclair, DK Finlay |
Nature Communications | 2018 |
Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization
A Bosi, S Zanellato, B Bassani, A Albini, A Musco, M Cattoni, M Desio, E Nardecchia, DG DUrso, A Imperatori, L Dominioni, DM Noonan, L Mortara, A Bruno |
Journal of Immunology Research | 2018 |
High mammographic density in women is associated with protumor inflammation
CW Huo, P Hill, G Chew, PJ Neeson, H Halse, ED Williams, MA Henderson, EW Thompson, KL Britt |
Breast Cancer Research | 2018 |
NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
NM Mahaweni, FA Ehlers, S Sarkar, JW Janssen, MG Tilanus, GM Bos, L Wieten |
Frontiers in immunology | 2018 |
Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
B Han, F Mao, Y Zhao, Y Lv, Y Teng, M Duan, W Chen, P Cheng, T Wang, Z Liang, J Zhang, Y Liu, G Guo, Q Zou, Y Zhuang, L Peng |
Journal of Immunology Research | 2018 |
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
KC Hicks, M Fantini, RN Donahue, A Schwab, KM Knudson, SR Tritsch, C Jochems, PE Clavijo, CT Allen, JW Hodge, KY Tsang, J Schlom, SR Gameiro |
OncoImmunology | 2018 |
Suppression of autophagy and HCK signaling promotes PTGS2 high FCGR3 − NK cell differentiation triggered by ectopic endometrial stromal cells
J Mei, WJ Zhou, XY Zhu, H Lu, K Wu, HL Yang, Q Fu, CY Wei, KK Chang, LP Jin, J Wang, YM Wang, DJ Li, MQ Li |
Autophagy | 2018 |
Oncogenes in immune cells as potential therapeutic targets
GK Zakiryanova, S Wheeler, MR Shurin |
ImmunoTargets and Therapy | 2018 |
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer
X Liu, R Ran, B Shao, HS Rugo, Y Yang, Z Hu, Z Wei, F Wan, W Kong, G Song, H Jiang, X Liang, R Zhang, Y Yan, G Xu, H Li |
Chinese Journal of Cancer Research | 2018 |
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
N Vey, L Karlin, S Sadot-Lebouvier, F Broussais, D Berton-Rigaud, J Rey, A Charbonnier, D Marie, P André, C Paturel, R Zerbib, J Bennouna, G Salles, A Gonçalves |
Oncotarget | 2018 |
Shining light on the significance of NK cell CD56 brightness
SM Poznanski, AA Ashkar |
Cellular and Molecular Immunology | 2018 |
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
P André, C Denis, C Soulas, C Bourbon-Caillet, J Lopez, T Arnoux, M Bléry, C Bonnafous, L Gauthier, A Morel, B Rossi, R Remark, V Breso, E Bonnet, G Habif, S Guia, AI Lalanne, C Hoffmann, O Lantz, J Fayette, A Boyer-Chammard, R Zerbib, P Dodion, H Ghadially, M Jure-Kunkel, Y Morel, R Herbst, E Narni-Mancinelli, RB Cohen, E Vivier |
Cell | 2018 |
Circulating NKp46 + Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer
E Picard, Y Godet, C Laheurte, M Dosset, J Galaine, L Beziaud, R Loyon, L Boullerot, EL Joseph, M Jacquin, G Eberst, FL pimpec-Barthes, E Fabre, V Westeel, A Caignard, C Borg, O Adotévi |
OncoImmunology | 2018 |
Engineering Natural Killer Cells for Cancer Immunotherapy
K Rezvani, R Rouce, E Liu, E Shpall |
Molecular Therapy | 2017 |
Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
M Messaoudene, A Frazao, PJ Gavlovsky, A Toubert, N Dulphy, A Caignard |
Frontiers in immunology | 2017 |
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
A Muntasell, M Cabo, S Servitja, I Tusquets, M Martínez-García, A Rovira, F Rojo, J Albanell, M López-Botet |
Frontiers in immunology | 2017 |
STATs in NK-Cells: The Good, the Bad, and the Ugly
D Gotthardt, V Sexl |
Frontiers in immunology | 2017 |
Adipocytes and Macrophages Interplay in the Orchestration of Tumor Microenvironment: New Implications in Cancer Progression
LH Corrêa, R Corrêa, CM Farinasso, LP de Dourado, KG Magalhães |
Frontiers in immunology | 2017 |
Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells
S Viel, L Besson, M Marotel, T Walzer, A Marçais |
Cancers | 2017 |
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
G Pittari, L Vago, M Festuccia, C Bonini, D Mudawi, L Giaccone, B Bruno |
Frontiers in immunology | 2017 |
Association between inflammation and cancer stem cell phenotype in breast cancer
Y Jeong, H Oh, S Park, J Bong |
Oncology Letters | 2017 |
Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras G12D/+ mice
NB Janakiram, A Mohammed, T Bryant, R Ritchie, N Stratton, L Jackson, S Lightfoot, DM Benbrook, AS Asch, ML Lang, CV Rao |
Immunology | 2017 |
MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells
C Breunig, J Pahl, M Küblbeck, M Miller, D Antonelli, N Erdem, C Wirth, R Will, A Bott, A Cerwenka, S Wiemann |
Cell Death and Disease | 2017 |
IL15 induces a potent anti-tumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid
C Daniele, S Martini, L Chiossone, F Scordamaglia, CF Simonassi, L Moretta, MC Mingari, P Vacca |
OncoImmunology | 2017 |
Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells
J Rey, C Fauriat, E Kochbati, F Orlanducci, A Charbonnier, E DIncan, P Andre, F Romagne, B Barbarat, N Vey, D Olive |
Frontiers in immunology | 2017 |
Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells
M Rady, C Watzl, M Claus, O Khorshid, L Mahran, K Abou-Aisha |
Scientific Reports | 2017 |
Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development
PM Tang, S Zhou, XM Meng, QM Wang, CJ Li, GY Lian, XR Huang, YJ Tang, XY Guan, BP Yan, KF To, HY Lan |
Nature Communications | 2017 |
Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies
P Carrega, G Ferlazzo |
Frontiers in immunology | 2017 |
Role of Distinct Natural Killer Cell Subsets in Anticancer Response
H Stabile, C Fionda, A Gismondi, A Santoni |
Frontiers in immunology | 2017 |
What Fuels Natural Killers? Metabolism and NK Cell Responses
CM Gardiner, DK Finlay |
Frontiers in immunology | 2017 |
NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus
D Yang, Z Tian, M Zhang, W Yang, J Tang, Y Wu, B Ni |
Scientific Reports | 2017 |
Leveraging natural killer cells for cancer immunotherapy
SK Grossenbacher, EG Aguilar, WJ Murphy |
Immunotherapy | 2017 |
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
JP Veluchamy, N Kok, HJ van der Vliet, HM Verheul, TD de Gruijl, J Spanholtz |
Frontiers in immunology | 2017 |
On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C
P Chu, N Nakamoto, N Taniki, K Ojiro, T Amiya, Y Makita, H Murata, A Yamaguchi, S Shiba, R Miyake, T Katayama, A Ugamura, A Ikura, K Takeda, H Ebinuma, H Saito, T Kanai, CH Liu |
PloS one | 2017 |
New insights into the role of EMT in tumor immune escape
S Terry, P Savagner, S Ortiz-Cuaran, L Mahjoubi, P Saintigny, JP Thiery, S Chouaib |
Molecular Oncology | 2017 |
NK Cell Exhaustion
J Bi, Z Tian |
Frontiers in immunology | 2017 |
CD155, an onco-immunologic molecule in human tumors
J Gao, Q Zheng, N Xin, W Wang, C Zhao |
Cancer Science | 2017 |
Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours
MM Shenouda, A Gillgrass, T Nham, R Hogg, AJ Lee, MV Chew, M Shafaei, C Aarts, DA Lee, J Hassell, A Bane, S Dhesy-Thind, AA Ashkar |
Breast Cancer Research | 2017 |
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
R Tallerico, CM Cristiani, E Staaf, C Garofalo, R Sottile, M Capone, YP de Coaña, G Madonna, E Palella, M Wolodarski, V Carannante, D Mallardo, E Simeone, AM Grimaldi, S Johansson, P Frumento, E Gulletta, A Anichini, F Colucci, G Ciliberto, R Kiessling, K Kärre, PA Ascierto, E Carbone |
OncoImmunology | 2016 |
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
S Rusakiewicz, A Perier, M Semeraro, JM Pitt, EP von Strandmann, KS Reiners, S Aspeslagh, C Pipéroglou, F Vély, A Ivagnes, S Jegou, N Halama, L Chaigneau, P Validire, C Christidis, T Perniceni, B Landi, A Berger, N Isambert, J Domont, S Bonvalot, P Terrier, J Adam, JM Coindre, JF Emile, V Poirier-Colame, K Chaba, B Rocha, A Caignard, A Toubert, D Enot, J Koch, A Marabelle, M Lambert, S Caillat-Zucman, S Leyvraz, C Auclair, E Vivier, A Eggermont, C Borg, JY Blay, AL Cesne, O Mir, L Zitvogel |
OncoImmunology | 2016 |
Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer
MM Valenzuela-Membrives, F Perea-García, A Sanchez-Palencia, F Ruiz-Cabello, M Gómez-Morales, MT Miranda-León, I Galindo-Angel, ME Fárez-Vidal |
Oncotarget | 2016 |
VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer
W Xei, F Liu, Y Wang, X Ren, T Wang, Z Chen, M Tang, F Sun, Z Li, M Wang, J Zhang |
Oncotarget | 2016 |
NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution
M Messaoudene, G Fregni, D Enot, N Jacquelot, E Neves, N Germaud, HJ Garchon, W Boukouaci, R Tamouza, J Chanal, MF Avril, A Toubert, L Zitvogel, S Rusakiewicz, A Caignard |
OncoImmunology | 2016 |
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
C Cantoni, L Huergo-Zapico, M Parodi, M Pedrazzi, MC Mingari, A Moretta, B Sparatore, S Gonzalez, D Olive, C Bottino, R Castriconi, M Vitale |
Journal of Immunology Research | 2016 |
Human NK Cell Subsets in Pregnancy and Disease: Toward a New Biological Complexity
CM Cristiani, E Palella, R Sottile, R Tallerico, C Garofalo, E Carbone |
Frontiers in immunology | 2016 |
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
A Bottos, D Gotthardt, JW Gill, A Gattelli, A Frei, A Tzankov, V Sexl, A Wodnar-Filipowicz, NE Hynes |
Nature Communications | 2016 |
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
GN Dietsch, H Lu, Y Yang, C Morishima, LQ Chow, ML Disis, RM Hershberg, H Nishikawa |
PloS one | 2016 |
Modulation of innate immunity in the tumor microenvironment
E Gonzalez-Gugel, M Saxena, N Bhardwaj |
Cancer Immunology, Immunotherapy | 2016 |
Progress towards understanding heterotypic interactions in multi-culture models of breast cancer
MC Regier, ET Alarid, DJ Beebe |
Integrative Biology | 2016 |
Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments
E Cariani, M Pilli, V Barili, E Porro, E Biasini, A Olivani, RD Valle, T Trenti, C Ferrari, G Missale |
OncoImmunology | 2016 |
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients
V Bücklein, T Adunka, AN Mendler, R Issels, M Subklewe, JC Schmollinger, E Noessner |
OncoImmunology | 2016 |
Altered Expression of Natural Cytotoxicity Receptors and NKG2D on Peripheral Blood NK Cell Subsets in Breast Cancer Patients
NG Nieto-Velázquez, YD Torres-Ramos, JL Muñoz-Sánchez, L Espinosa-Godoy, S Gómez-Cortés, J Moreno, MA Moreno-Eutimio |
Translational oncology | 2016 |
Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
QF Zhang, WW Yin, Y Xia, YY Yi, QF He, X Wang, H Ren, DZ Zhang |
Cellular and Molecular Immunology | 2016 |
A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6
W Tian, L Wang, L Yuan, W Duan, W Zhao, S Wang, Q Zhang |
Cancer Science | 2016 |
Ionomycin Treatment Renders NK Cells Hyporesponsive
G Romera-Cárdenas, LM Thomas, S Lopez-Cobo, EM García-Cuesta, EO Long, HT Reyburn, J Yu |
PloS one | 2016 |
High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
C Sun, J Xu, Q Huang, M Huang, H Wen, C Zhang, J Wang, J Song, M Zheng, H Sun, H Wei, W Xiao, R Sun, Z Tian |
OncoImmunology | 2016 |
Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15
YS Rocca, MP Roberti, EP Juliá, MB Pampena, L Bruno, S Rivero, E Huertas, FS Loria, A Pairola, A Caignard, J Mordoh, EM Levy |
Frontiers in immunology | 2016 |
NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint
A Shemesh, A Kugel, N Steiner, M Yezersky, D Tirosh, A Edri, O Teltsh, B Rosental, E Sheiner, E Rubin, KS Campbell, A Porgador |
Oncotarget | 2016 |
From mice to humans: developments in cancer immunoediting
Michele Teng, Jerome GALON, Wolf-Herman Fridman, Mark Smyth |
Journal of Clinical Investigation | 2015 |
The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia
RH Rouce, H Shaim, T Sekine, G Weber, B Ballard, S Ku, C Barese, V Murali, MF Wu, H Liu, EJ Shpall, CM Bollard, KR Rabin, K Rezvani |
Leukemia | 2015 |
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
E Verronèse, A Delgado, J Valladeau-Guilemond, G Garin, S Guillemaut, O Tredan, I Ray-Coquard, T Bachelot, A N'Kodia, C Bardin-Dit-Courageot, C Rigal, D Pérol, C Caux, C Ménétrier-Caux |
OncoImmunology | 2015 |
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity
C Germain, S Gnjatic, MC Dieu-Nosjean |
Frontiers in immunology | 2015 |
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
C Chester, K Fritsch, HE Kohrt |
Frontiers in immunology | 2015 |
Natural Killer Cells as Helper Cells in Dendritic Cell Cancer Vaccines
MÃ Pampena, EM Levy |
Frontiers in immunology | 2015 |
Balancing natural killer cell activation through paired receptors
L Martinet, MJ Smyth |
Nature Reviews Immunology | 2015 |
Newtonian cell interactions shape natural killer cell education
JP Goodridge, B Önfelt, KJ Malmberg |
Immunological Reviews | 2015 |
Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus
ML Ascierto, F Bozzano, D Bedognetti, F Marras, C Schechterly, K Matsuura, A Picciotto, S Marenco, Y Zhao, V DeGiorgi, M Sommariva, L Moretta, E Wang, HJ Alter, FM Marincola, AD Maria |
Journal of Translational Medicine | 2015 |
Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy
EI Ager, SV Kozin, ND Kirkpatrick, G Seano, DP Kodack, V Askoxylakis, Y Huang, S Goel, M Snuderl, A Muzikansky, DM Finkelstein, DT Dransfield, L Devy, Y Boucher, D Fukumura, RK Jain |
JNCI Journal of the National Cancer Institute | 2015 |
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
MN Duong, A Cleret, EL Matera, K Chettab, D Mathé, S Valsesia-Wittmann, B Clémenceau, C Dumontet |
Breast Cancer Research | 2015 |
Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model
AE Gillgrass, MV Chew, T Krneta, AA Ashkar |
BMC Cancer | 2015 |
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
AG Navarro, AT Björklund, M Chekenya |
Frontiers in immunology | 2015 |
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
A Giannattasio, S Weil, S Kloess, N Ansari, EH Stelzer, A Cerwenka, A Steinle, U Koehl, J Koch |
BMC Cancer | 2015 |
Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells
M Siernicka, M Winiarska, M Bajor, M Firczuk, A Muchowicz, M Bobrowicz, C Fauriat, J Golab, D Olive, R Zagozdzon |
Immunology | 2015 |
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
A Coppola, R Arriga, D Lauro, MI Principe, F Buccisano, L Maurillo, P Palomba, A Venditti, G Sconocchia |
Frontiers in Medicine | 2015 |
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment
M Parodi, M Pedrazzi, C Cantoni, M Averna, M Patrone, M Cavaletto, S Spertino, D Pende, M Balsamo, G Pietra, S Sivori, S Carlomagno, MC Mingari, L Moretta, B Sparatore, M Vitale |
OncoImmunology | 2015 |
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
HB Jie, PJ Schuler, SC Lee, RM Srivastava, A Argiris, S Ferrone, TL Whiteside, RL Ferris |
Cancer research | 2015 |
The breast tumor microenvironment alters the phenotype and function of natural killer cells
T Krneta, A Gillgrass, M Chew, AA Ashkar |
Cellular and Molecular Immunology | 2015 |
Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
G Pietra, C Vitale, D Pende, A Bertaina, F Moretta, M Falco, P Vacca, E Montaldo, C Cantoni, MC Mingari, A Moretta, F Locatelli, L Moretta |
Cancer Immunology, Immunotherapy | 2015 |
Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes
JP Cata, C Conrad, K Rezvani |
Scientifica | 2015 |
Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia
AS Chretien, S Granjeaud, F Gondois-Rey, S Harbi, F Orlanducci, D Blaise, N Vey, C Arnoulet, C Fauriat, D Olive |
Frontiers in immunology | 2015 |
Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors
X Kang, J Kim, M Deng, S John, H Chen, G Wu, H Phan, CC Zhang |
Cell cycle (Georgetown, Tex.) | 2015 |
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
K Rezvani, RH Rouce |
Frontiers in immunology | 2015 |
NK cell exhaustion: bad news for chronic disease?
JL Schafer, MC Müller-Trutwin, RK Reeves |
Oncotarget | 2015 |
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer
Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D |
Oncotarget | 2015 |
Cytokines reinstate NK cell-mediated cancer immunosurveillance
Laurence Zitvogel, Guido Kroemer |
Journal of Clinical Investigation | 2014 |
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade
IP da Silva, A Gallois, S Jimenez-Baranda, S Khan, AC Anderson, VK Kuchroo, I Osman, N Bhardwaj |
Cancer immunology research | 2014 |
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
AS Chretien, AL Roy, N Vey, T Prebet, D Blaise, C Fauriat, D Olive |
Frontiers in immunology | 2014 |
Clinical utility of natural killer cells in cancer therapy and transplantation
DA Knorr, V Bachanova, MR Verneris, JS Miller |
Seminars in Immunology | 2014 |
Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy
S Chandrasekaran, M King |
International journal of molecular sciences | 2014 |
A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
A Bruno, G Ferlazzo, A Albini, DM Noonan |
JNCI Journal of the National Cancer Institute | 2014 |
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
CJ Chan, L Martinet, S Gilfillan, F Souza-Fonseca-Guimaraes, MT Chow, L Town, DS Ritchie, M Colonna, DM Andrews, MJ Smyth |
Nature Immunology | 2014 |
Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?
A Unsworth, R Anderson, K Britt |
Journal of Mammary Gland Biology and Neoplasia | 2014 |
Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
L Moretta, G Pietra, E Montaldo, P Vacca, D Pende, M Falco, GD Zotto, F Locatelli, A Moretta, MC Mingari |
Frontiers in immunology | 2014 |
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
C Sun, H Sun, C Zhang, Z Tian |
Cellular and Molecular Immunology | 2014 |
NK cells and T cells cooperate during the clinical course of colorectal cancer
G Sconocchia, S Eppenberger, GC Spagnoli, L Tornillo, R Droeser, S Caratelli, F Ferrelli, A Coppola, R Arriga, D Lauro, G Iezzi, L Terracciano, S Ferrone |
OncoImmunology | 2014 |
Reversal of natural killer cell exhaustion by TIM-3 blockade
A Gallois, I Silva, I Osman, N Bhardwaj |
OncoImmunology | 2014 |
mTORC1-Dependent Metabolic Reprogramming Is a Prerequisite for NK Cell Effector Function
RP Donnelly, RM Loftus, SE Keating, KT Liou, CA Biron, CM Gardiner, DK Finlay |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL |
Critical reviews in immunology | 2014 |
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
KS Reiners, J Kessler, M Sauer, A Rothe, HP Hansen, U Reusch, C Hucke, U Köhl, H Dürkop, A Engert, EP von Strandmann |
Molecular Therapy | 2013 |
Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
KK Payne, CK Zoon, W Wan, K Marlar, RC Keim, MN Kenari, AL Kazim, HD Bear, MH Manjili |
Breast Cancer Research and Treatment | 2013 |
Molecular mechanisms of natural killer cell activation in response to cellular stress
CJ Chan, MJ Smyth, L Martinet |
Cell Death and Differentiation | 2013 |
Influence of tumors on protective anti-tumor immunity and the effects of irradiation
GA Foulds, J Radons, M Kreuzer, G Multhoff, AG Pockley |
Frontiers in Oncology | 2013 |
CD11b(-)CD27(-) NK cells are associated with the progression of lung carcinoma
J Jin, B Fu, X Mei, T Yue, R Sun, Z Tian, H Wei |
PloS one | 2013 |
The immune system and inflammation in breast cancer
X Jiang, DJ Shapiro |
Molecular and Cellular Endocrinology | 2013 |
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
X Ma, D Holt, N Kundu, J Reader, O Goloubeva, Y Take, AM Fulton |
OncoImmunology | 2013 |
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
M Ascierto, MO Idowu, Y Zhao, H Khalak, KK Payne, XY Wang, CI Dumur, D Bedognetti, S Tomei, PA Ascierto, A Shanker, HD Bear, E Wang, FM Marincola, AD Maria, MH Manjili |
Journal of Translational Medicine | 2013 |
NK cells from malignant pleural effusions are potent antitumor effectors
P Vacca, S Martini, MC Mingari, L Moretta |
OncoImmunology | 2013 |
When breast cancer cells start to fend the educational process of NK cells off
E Mamessier, C Bourgin, D Olive |
OncoImmunology | 2013 |
Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer
YP Peng, Y Zhu, JJ Zhang, ZK Xu, ZY Qian, CC Dai, KR Jiang, JL Wu, WT Gao, Q Li, Q Du, Y Miao |
Journal of Translational Medicine | 2013 |
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
JE Hudak, SM Canham, CR Bertozzi |
Nature Chemical Biology | 2013 |
Homo-oligomerization of the Activating Natural Killer Cell Receptor NKp30 Ectodomain Increases Its Binding Affinity for Cellular Ligands
J Herrmann, H Berberich, J Hartmann, S Beyer, K Davies, J Koch |
The Journal of biological chemistry | 2013 |
Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells
M Gillard-Bocquet, C Caer, N Cagnard, L Crozet, M Perez, WH Fridman, C Sautès-Fridman, I Cremer |
Frontiers in immunology | 2013 |
NK cells sense tumors, course of disease and treatments
G Fregni, A Perier, MF Avril, A Caignard |
OncoImmunology | 2012 |
Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy
C Veuillen, T Aurran-Schleinitz, R Castellano, J Rey, F Mallet, F Orlanducci, L Pouyet, S Just-Landi, D Coso, V Ivanov, X Carcopino, R Bouabdallah, Y Collette, C Fauriat, D Olive |
Journal of Clinical Immunology | 2012 |
Investigation of NK cell function and their modulation in different malignancies
G Konjevic, V Jurisic, V Jovic, A Vuletic, KM Martinovic, S Radenkovic, I Spuzic |
Immunologic Research | 2012 |
Natural killer cells in non-hematopoietic malignancies
M Desbois, S Rusakiewicz, C Locher, L Zitvogel, N Chaput |
Frontiers in immunology | 2012 |
“Stealth” tumors
E Mamessier, F Bertucci, R Sabatier, D Birnbaum, D Olive |
OncoImmunology | 2012 |
Tumor microenvironment in NSCLC suppresses NK cells function
I Cremer, WH Fridman, C Sautès-Fridman |
OncoImmunology | 2012 |
How melanoma cells inactivate NK cells
G Pietra, M Vitale, L Moretta, MC Mingari |
OncoImmunology | 2012 |
The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact
WH Fridman, MC Dieu-Nosjean, F Pagès, I Cremer, D Damotte, C Sautès-Fridman, J Galon |
Cancer Microenvironment | 2012 |
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
S Gill, AE Vasey, AD Souza, J Baker, AT Smith, HE Kohrt, M Florek, KD Gibbs, K Tate, DS Ritchie, RS Negrin |
Blood | 2012 |
The immune contexture in human tumours: impact on clinical outcome
WH Fridman, F Pagès, C Sautès-Fridman, J Galon |
Nature Reviews Cancer | 2012 |
Biological role of NK cells and immunotherapeutic approaches in breast cancer
MP Roberti, J Mordoh, EM Levy |
Frontiers in immunology | 2012 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |